Protagonist Therapeutics (PTGX) Net Cash Flow (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Net Cash Flow of $65.3 million for Q1 2026, up 345.07% sequentially from $14.7 million in Q4 2025, and up 54.05% YoY from $42.4 million in Q1 2025.
Protagonist Therapeutics (PTGX) Net Cash Flow (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Net Cash Flow for 12 years, with the latest figure at $65.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 54.05% year-over-year to $65.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.1 million (up 264.43% YoY) and the FY2025 annual result came in at $31.2 million, up 134.87% from the prior year.
- Net Cash Flow improved to $65.3 million in Q1 2026 per PTGX's latest filing, from $14.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $183.1 million in Q2 2024 and troughed at -$224.5 million in Q3 2024.
- A 5-year average of $4.1 million and a median of $1.9 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 4524.55% in 2024, then soared 399.48% in 2025.
- Over 5 years, Net Cash Flow stood at -$27.1 million in 2022, then slumped by 61.34% to -$43.8 million in 2023, then advanced by 22.67% to -$33.9 million in 2024, then soared by 143.33% to $14.7 million in 2025, then surged by 345.07% to $65.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $65.3 million, $14.7 million, and -$54.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 226.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 226.37 Mn |
| Jun 30, 2026 | 226.37 Mn |
| Mar 31, 2026 | 65.32 Mn |
| Mar 31, 2026 | 65.32 Mn |
| Dec 31, 2025 | 14.68 Mn |
| Dec 31, 2025 | 14.68 Mn |
| Sep 30, 2025 | -54.83 Mn |
| Sep 30, 2025 | -54.83 Mn |
| Jun 30, 2025 | 28.96 Mn |
| Jun 30, 2025 | 28.96 Mn |
| Mar 31, 2025 | 42.40 Mn |
| Mar 31, 2025 | 42.40 Mn |
| Dec 31, 2024 | -33.87 Mn |
| Dec 31, 2024 | -33.87 Mn |
| Sep 30, 2024 | -224.52 Mn |
| Sep 30, 2024 | -224.52 Mn |
| Jun 30, 2024 | 183.08 Mn |
| Jun 30, 2024 | 183.08 Mn |
| Mar 31, 2024 | -14.16 Mn |
| Mar 31, 2024 | -14.16 Mn |